BBHC
TGTX icon

Brown Brothers Harriman & Co’s TG Therapeutics TGTX Stock Holding History

Brown Brothers Harriman & Co’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-132
Closed -$3.94K – 1912
2025
Q4 		$3.94K Hold
132
– – ﹤0.01% 1579
2025
Q3 		$4.77K Hold
132
– – ﹤0.01% 1424
2025
Q2 		$4.75K Buy
+132
New +$4.91K ﹤0.01% 1282
2021
Q1 		– Sell
-1,000
Closed -$52K – 1237
2020
Q4 		$52K Buy
+1,000
New +$33.8K ﹤0.01% 659

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Brown Brothers Harriman & Co's TGTX Position: Q1 2026 in Review

Brown Brothers Harriman & Co sold out of TG Therapeutics (TGTX) in Q1 2026, closing a stake of 132 shares — an estimated $3.94K sold.

Brown Brothers Harriman & Co first reported a position in TGTX in Q4 2020 and held it in 4 quarters. The position peaked at $52K in Q4 2020. 365 funds tracked by Wall St. Rank hold TGTX as of Q1 2026.

  • Brown Brothers Harriman & Co reported no remaining TG Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Brown Brothers Harriman & Co sold 132 TG Therapeutics shares in Q1 2026, an estimated $3.94K.
  • Brown Brothers Harriman & Co first reported a position in TG Therapeutics in Q4 2020 and held it in 4 quarters.
  • Brown Brothers Harriman & Co's TG Therapeutics position peaked at $52K in Q4 2020.
  • 365 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2026.

Based on Brown Brothers Harriman & Co's 13F filing for Q1 2026, filed 14 May 2026.